33 States to Get $62 Million in Zyprexa Case Settlement

Eli Lilly has agreed to pay $62 million to 33 states to settle claims that it improperly marketed Zyprexa, its top-selling drug, to patients who did not have schizophrenia or bipolar disorder, its only approved uses.

Illinois will receive nearly $3.6 million in settlement funds from the company. Missouri will receive $1.5 million.

Lilly also agreed to several mandates that will last until 2014, well beyond the expiration of Zyprexa’s patent in 2011. The company agreed to avoid making false, misleading or deceptive claims about the drug and not to promote it outside FDA-approved uses.